Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Sweeney

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
Radiation Research|April 29, 2009
Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cellsChristopher Watson, Douglas A Miller, Helen Chin-Sinex, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2014
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumorsE Gabriela Chiorean, Christopher Sweeney, Hagop Youssoufian, et al.
The Prostate|September 5, 2002
Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor systemShaobo Zhang, Guangyuan Zeng, Chinghai Kao, et al.
Prostate Cancer and Prostatic Diseases|February 11, 2022
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED RegistryXiao X Wei, Lucia Kwak, Anis Hamid, et al.
Plos Computational Biology|April 15, 2016
Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate CancerDaniela Börnigen, Svitlana Tyekucheva, Xiaodong Wang, et al.
Laboratory Animals|October 10, 2018
Informing efficient pilot development of animal trauma models through quality improvement strategiesPenny S Reynolds, Jacquelyn McCarter, Christopher Sweeney, et al.
Cancer Chemotherapy and Pharmacology|May 31, 2006
A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumorsBryan Schneider, Anna Fukunaga, Daryl Murry, et al.
Oncology|August 10, 2005
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancerChong-Xian Pan, Patrick Loehrer, David Seitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostateChristopher Sweeney, Lang Li, Rajasubramaniam Shanmugam, et al.
Cancer|May 31, 2013
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal diseaseMari Nakabayashi, Julia Hayes, Mary-Ellen Taplin, et al.
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Radiation Research|April 29, 2009
Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cellsChristopher Watson, Douglas A Miller, Helen Chin-Sinex, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2014
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumorsE Gabriela Chiorean, Christopher Sweeney, Hagop Youssoufian, et al.
The Prostate|September 5, 2002
Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor systemShaobo Zhang, Guangyuan Zeng, Chinghai Kao, et al.
Prostate Cancer and Prostatic Diseases|February 11, 2022
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED RegistryXiao X Wei, Lucia Kwak, Anis Hamid, et al.
Plos Computational Biology|April 15, 2016
Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate CancerDaniela Börnigen, Svitlana Tyekucheva, Xiaodong Wang, et al.
Laboratory Animals|October 10, 2018
Informing efficient pilot development of animal trauma models through quality improvement strategiesPenny S Reynolds, Jacquelyn McCarter, Christopher Sweeney, et al.
Cancer Chemotherapy and Pharmacology|May 31, 2006
A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumorsBryan Schneider, Anna Fukunaga, Daryl Murry, et al.
Oncology|August 10, 2005
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancerChong-Xian Pan, Patrick Loehrer, David Seitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostateChristopher Sweeney, Lang Li, Rajasubramaniam Shanmugam, et al.
Cancer|May 31, 2013
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal diseaseMari Nakabayashi, Julia Hayes, Mary-Ellen Taplin, et al.
Pageof 10